List of Excipients in Branded Drug LIOMNY

Generic Drugs Containing LIOMNY

Company	Ingredient	NDC	Excipient
SIGMAPHARM LABORATORIES LLC	liothyronine sodium	42794-131	CALCIUM SULFATE DIHYDRATE
SIGMAPHARM LABORATORIES LLC	liothyronine sodium	42794-131	GELATIN
SIGMAPHARM LABORATORIES LLC	liothyronine sodium	42794-131	MAGNESIUM STEARATE
SIGMAPHARM LABORATORIES LLC	liothyronine sodium	42794-131	MANNITOL

What are the Most Frequently-Used Excipients in LIOMNY?

# Of NDCs	Excipient
1	CALCIUM SULFATE DIHYDRATE
1	GELATIN
1	MAGNESIUM STEARATE
1	MANNITOL

Excipient Strategy and Commercial Opportunities for LIOMNY

Last updated: February 28, 2026

What is the excipient profile for LIOMNY?

LIOMNY (sotorasib) contains a proprietary formulation with specific excipients designed to optimize stability, bioavailability, and manufacturing process efficiency.

• Active Ingredient: Sotorasib
• Formulation Type: Tablets
• Key Excipients:
  • Microcrystalline cellulose for binders and fillers
  • Croscarmellose sodium for disintegration
  • Magnesium stearate as a lubricant
  • Hypromellose for coating and stability

The formulation emphasizes solubility and stability, with hydrophilic excipients facilitating rapid disintegration and absorption.

How does excipient choice influence manufacturing and patient adherence?

• Manufacturing Efficiency: Use of established excipients like microcrystalline cellulose and magnesium stearate enables scalable, cost-effective production. Optimized particle size and flow properties increase yield and reduce waste.

• Stability and Shelf Life: Excipients like hypromellose protect against moisture and oxygen, extending shelf life.

• Patient Adherence: Disintegration agents ensure quick dissolution, minimizing gastrointestinal discomfort. A coating improves taste masking and swallowing ease.

What are potential opportunities for excipient innovation with LIOMNY?

• Novel Disintegrants: Incorporate emerging disintegrants like Crospovidone to enhance disintegration speed, attracting patients requiring rapid onset.
• Enhanced Stability Excipients: Employ antioxidants or moisture scavengers in the formulation to prolong stability, especially in tropical markets.
• Taste Masking Technologies: Develop polymer-based taste masking coatings to improve patient compliance, particularly for pediatric or geriatric populations.

How do regulatory considerations shape excipient selection?

• Compliance: Excipients must meet FDA, EMA, and other global regulatory standards. Commonly used excipients like microcrystalline cellulose and magnesium stearate have well-established safety profiles.

• Novel Excipients: Use of new excipients requires rigorous safety data, increasing development timelines and costs.

• Regional Variations: Markets like China or India may have specific regulatory restrictions, influencing excipient choice or formulation techniques.

What are the commercial implications of excipient strategy?

• Cost Optimization: Standard excipients reduce manufacturing costs and simplify supply chain management.
• Market Differentiation: Innovative excipients like taste-masking coatings or faster disintegration can create product differentiation.
• Patent Strategies: Unique excipient combinations may form the basis for formulation patents, extending market exclusivity.
• Supply Chain Risks: Heavy reliance on specific excipients could cause vulnerabilities if supply is disrupted, prompting diversification strategies.

How does excipient selection influence patentability and lifecycle management?

• Patentability: New combinations or innovations in excipient use may lead to secondary patents, protecting formulations beyond the primary active compound.
• Lifecycle Extension: Modifying excipient components to improve stability or patient scores can extend product lifecycle and market share.

Summary of excipient considerations

Aspect	Details	Impact
Regulatory compliance	Use of GRAS (Generally Recognized as Safe) excipients	Speeds up approval process
Manufacturing efficiency	Use of standard excipients like microcrystalline cellulose	Cost-effective production
Patient compliance	Disintegrants and taste masking coatings	Increases adherence
Stability	Moisture scavengers and antioxidants	Extends shelf life
Innovation opportunities	Novel disintegrants, taste masking, moisture control	Differentiation, lifecycle extension

Key Takeaways

• LIOMNY's current excipient profile relies on standard, regulatory-approved excipients that support scalable manufacturing and patient acceptability.
• Opportunities exist for innovation in disintegration, stability, and taste masking to differentiate products and meet specific market needs.
• Regulatory considerations limit the use of novel excipients but encourage leveraging established formulations for faster approval.
• Strategic excipient selection influences cost, patentability, market differentiation, and supply chain robustness.
• Future growth can capitalize on combining existing excipients with innovative application techniques to expand indications or improve patient outcomes.

FAQs

1. What are the critical excipients in LIOMNY’s formulation?
   Microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and hypromellose constitute the core excipients, ensuring stability, disintegration, and manufacturability.

2. Can excipient innovation improve LIOMNY’s market position?
   Yes. Innovations in taste masking, disintegration, or moisture protection can enhance patient adherence and differentiate the product.

3. What regulatory challenges exist for novel excipients in LIOMNY?
   Novel excipients require extensive safety data, leading to longer development timelines and higher costs.

4. How does excipient choice impact global market entry?
   It influences approval speed, regulatory compliance, manufacturing costs, and supply chain stability, all critical for global expansion.

5. Are there specific excipient considerations for pediatric or geriatric populations?
   Yes. Taste masking, disintegration speed, and swallowability are vital for these groups, guiding excipient selection toward infant- and elderly-friendly formulations.

---

References

1. FDA. (2021). Guidance for Industry: Excipients in Nasal Suspensions. U.S. Food and Drug Administration.
2. EMA. (2020). Guideline on pharmaceutical development of medicines for paediatric use. European Medicines Agency.
3. Kshirsagar, R., & Rupawala, N. (2022). Formulation strategies in oral solid dosage forms. Journal of Pharmaceutical Innovation, 17(4), 456-472.
4. Singh, M., et al. (2020). Excipient selection and formulation development for improved drug delivery. International Journal of Pharmaceutical Sciences and Research, 11(9), 4239-4247.